Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 99,172 Shares of Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the completion of the sale, the insider now owns 89,407 shares in the company, valued at $8,352,401.94. The trade was a 52.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Insmed Trading Up 1.9%

Shares of INSM traded up $1.85 during trading hours on Friday, hitting $98.73. The stock had a trading volume of 5,318,455 shares, compared to its average volume of 2,168,827. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market cap of $17.98 billion, a P/E ratio of -17.66 and a beta of 0.80. The company's fifty day simple moving average is $70.73 and its 200 day simple moving average is $73.47. Insmed Incorporated has a 12-month low of $60.40 and a 12-month high of $100.00.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business's revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.06) earnings per share. Equities research analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Cullen Frost Bankers Inc. grew its holdings in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 221 shares in the last quarter. Elequin Capital LP bought a new stake in Insmed during the fourth quarter valued at about $28,000. Steward Partners Investment Advisory LLC raised its position in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC raised its position in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 248 shares during the last quarter. Finally, NBC Securities Inc. acquired a new position in shares of Insmed during the first quarter valued at about $49,000.

Analyst Upgrades and Downgrades

INSM has been the subject of several recent research reports. Morgan Stanley increased their price target on Insmed from $90.00 to $102.00 and gave the company an "overweight" rating in a report on Wednesday. Jefferies Financial Group reiterated a "buy" rating on shares of Insmed in a report on Tuesday. Citigroup raised Insmed to a "buy" rating in a report on Tuesday. Guggenheim reissued a "buy" rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. Finally, Leerink Partners boosted their price target on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and a consensus target price of $104.81.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.